Page 3 - Nsclc News Today

Nuvation Bio Inc. said on March 25 it will acquire Anheart Therapeutics Ltd., a U.S.- and China-based precision oncology company, in an all-stock transaction, adding Anheart’s ROS1-inhibiting lung cancer drug, taletrectinib (AB-106), to its pipeline.

Patients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data.

A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

The FDA has accepted a new drug application for ensartinib in metastatic ALK-positive non–small cell lung cancer.

Salman R. Punekar, MD, discusses the importance of complete biomarker testing and the landscape of biomarkers in lung cancer.

During radiotherapy for non–small cell lung cancer, an incidental dose of radiation to the pulmonary veins may trigger atrial fibrillation, a study has found.

Drug major Merck & Co., Inc. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP adopted a positive opinion recommending approval of its anti-PD-1 therapy KEYTRUDA, in combination with platinum-containing chemotherapy.

Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.

Alanine-serine-cysteine transporter 2 (ASCT2) is a glutamine (Gln) transporter that is required for cell proliferation and is overexpressed in tumors such as non-small-cell lung cancer (NSCLC). Researchers from China Pharmaceutical University have reported on the discovery and preclinical characterization of a novel series of ASCT2 inhibitors that led to the identification two lead compounds.